Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SLXN

Silexion Therapeutics Corp

Nov 20 • 04:00PM ET

0.3331

Dollar change +0.1069
Percentage change 47.26	%

Healthcare • Biotechnology • Israel • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.14	Insider Own	43.55%	Shs Outstand	3.87M	Perf Week	35.90%
Market Cap	4.80M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.18M	Perf Month	-25.96%
Income	-0.52M	PEG	-	EPS next Q	-0.82	Inst Own	29.48%	Short Float	35.22%	Perf Quarter	-80.86%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.28	Perf Half Y	-96.93%
Book/sh	0.66	P/B	0.51	EPS next Y	-	ROA	-3.13%	Short Interest	0.77M	Perf Year	-96.65%
Cash/sh	0.41	P/C	0.81	EPS next 5Y	-	ROE	-3.78%	52W Range	0.21 - 13.56	Perf YTD	-96.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-20.64%	52W High	-97.54%	Beta	-0.17
Dividend TTM	-	Quick Ratio	1.75	Sales past 5Y	0.00%	Gross Margin	-	52W Low	60.92%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	1.75	EPS Y/Y TTM	-227.72%	Oper. Margin	0.00%	RSI (14)	44.05	Volatility	21.35% 14.83%
Employees	-	Debt/Eq	1.32	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	1.00
Option/Short	No / No	LT Debt/Eq	0.00	EPS Q/Q	-204.38%	Payout	0.00%	Rel Volume	72.76	Prev Close	0.23
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Aug 28	Avg Volume	2.74M	Price	0.33
SMA20	24.19%	SMA50	-25.01%	SMA200	-95.52%	Trades		Volume	199,616,636	Change	47.26%

Nov-20-24 08:30AM	Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference (GlobeNewswire) +47.26%
Nov-14-24 08:30AM	Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (ACCESSWIRE) -8.73%
Oct-09-24 05:35PM	Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit (ACCESSWIRE) -11.93% -5.98%
Oct-01-24 06:45AM	Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies (Business Wire) +5.90%
Sep-24-24 07:30AM	Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER in Non-Resectable Pancreatic Cancer (Business Wire) -16.28%
07:32AM	Loading…
Sep-09-24 07:32AM	PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers (Business Wire) +11.61%
Sep-03-24 04:05PM	Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference (GlobeNewswire) -24.66% -10.98%
Aug-15-24 04:05PM	Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination (GlobeNewswire) -13.21% -79.39%

Silexion Therapeutics Corp. engages in the discovery and development of treatments for KRAS-driven cancers. The company is headquartered in Modiin, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLXN

Silexion Therapeutics Corp

Upgrade your FINVIZ experience